$0.61
-0.01 (-1.44%)
Open$0.63
Previous Close$0.62
Day High$0.64
Day Low$0.59
52W High$6.19
52W Low$0.52
Volume—
Avg Volume236.1K
Market Cap47.76M
P/E Ratio—
EPS$-0.31
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+5,127.5% upside
Current
$0.61
$0.61
Target
$31.94
$31.94
$22.24
$31.94 avg
$42.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 15.40M | 13.64M | 13.89M |
| Net Income | -704,326 | -740,627 | -795,931 |
| Profit Margin | -4.6% | -5.4% | -5.7% |
| EBITDA | -1,183,474 | -997,072 | -1,062,628 |
| Free Cash Flow | -738,508 | -859,127 | -679,392 |
| Rev Growth | +4.1% | +16.3% | -0.4% |
| Debt/Equity | 0.22 | 0.30 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |